Enveric Biosciences (ENVB) Stock: Buy, Sell, or Hold?
ENVB - Enveric Biosciences, Inc. Common Stock
$1.48
0.02 (1.37%)
â˛
5d:
-1.33%
30d:
+2.78%
90d:
+0.0%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When ENVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ENVB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ENVB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ENVB is currently trading at $1.48, which is considered fair relative to its 30-day fair value range of $1.40 to $1.53.
Technical Outlook: Technically, ENVB is in a downtrend. Immediate support is located at $1.41, while resistance sits at $1.65.
Market Sentiment: ENVB scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+575.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENVB is in a downtrend. Immediate support is located at $1.41, while resistance sits at $1.65.
Market Sentiment: ENVB scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+575.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.40 -
$1.53
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 575.7% below Wall St target ($10.00)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.40 -
$1.53
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.41
Resistance Level
$1.65
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.09
Wall Street Target
$10.00
(+575.7%)
Revenue Growth (YoY)
-7.3%
Share & Embed Analysis
Last updated: October 04, 2026 11:47 AM ET
Data refreshes hourly during market hours. Next update: 12:47 PM
Data refreshes hourly during market hours. Next update: 12:47 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
29 analysts |
$371 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$307 | 66 BUY |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 71 BUY |
